Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Mass Spec Predicts Improved Response to Anti-HER2 Therapy in Breast Cancer

Published: Monday, July 07, 2014
Last Updated: Monday, July 07, 2014
Bookmark and Share
Immunohistochemistry is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives.

A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with support from the BBVA Foundation, defined for the first time a quantitative HER2 protein level measured by mass spectrometry is associated with longer disease free and overall survival in patients receiving anti-HER2 treatment.   Results of the study were presented during the ASCO 2014 Annual Meeting by Dr. Paolo Nuciforo, Principal Investigator of VHIO´s Molecular Oncology Group. 

While immunohistochemistry (IHC) is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives. Many patients who are classified by IHC as HER2-positive actually express low levels of the receptor which dramatically reduces efficacy of anti-HER2 therapy. 

OncoPlex Diagnostics uses the patented Liquid Tissue® process to solubilize formalin-fixed, paraffin-embedded (FFPE) tissue for precise protein quantitation by mass spectrometry analysis.  The study analyzed tissue from 60 breast cancer patients previously classified as IHC 3+ and treated with anti-HER2 therapy.  The research revealed high variability in HER2 expression within the patient population that had been homogenously classified as 3+ by IHC. Patients with HER2 protein levels greater than or equal to 2758.75 amol/ug, as measured by mass spectrometry, correlated with greater clinical benefit including prolonged survival rates.  The ASCO poster presentation is available at OncoPlex Dx HER2 ASCO2014 Collaboration.

"This study provides evidence that quantitative measurement by mass spectrometry of a tumor-driving protein such as HER2 correlates with the clinical benefit associated with HER2 targeted therapy," stated Dr. Jedd Levine, Chief Medical Officer for OncoPlex Diagnostics. The primary investigator, Dr. Nucifiro, explains, "If future (ongoing) studies enrolling a greater number of patients confirm these results, this would represent an important game-changer in how we currently determine HER2 expression levels as well as provide oncologists with further insight to better tailor anti-HER2-based therapies according to HER2 protein levels."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Chip-Based Technology Enables Reliable Direct Detection of Ebola Virus
Hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Cell Type May Help Explain Dangerous Food Allergies
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Molecular Diagnostics At Home
Electrochemical test's sensing principle may be generalized to many different targets, leading to inexpensive devices that could detect dozens of disease markers in less than 5 minutes.
DNA Alterations as Among Earliest to Occur in Lung Cancer Development
Genetic footprints of precancer detectable in some blood samples.
New, Improved Approach To Mammograms
Detecting breast cancer in women with dense mammary tissues could become more reliable with a new mammogram procedure that researchers have now tested in pre-clinical studies of mice.
Undiagnosed Diseases Network Launches Online Application Portal
UDN Gateway enables patients to apply to national network of clinical sites.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos